Nuo Therapeutics, Inc. (AURX)
USD 1.35
(-1.46%)
USD 1.35
(-1.46%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -673.08 Thousand USD | 60.78% |
| 2022 | -1.71 Million USD | -1056.21% |
| 2021 | -148.43 Thousand USD | 2.08% |
| 2020 | -151.58 Thousand USD | -127.98% |
| 2019 | 541.7 Thousand USD | 265.2% |
| 2018 | -327.91 Thousand USD | 52.72% |
| 2017 | -693.51 Thousand USD | 74.06% |
| 2016 | -2.67 Million USD | -107.85% |
| 2015 | 34.07 Million USD | 318.15% |
| 2014 | -15.62 Million USD | -768.55% |
| 2013 | 2.33 Million USD | 552.99% |
| 2012 | -515.8 Thousand USD | -253.17% |
| 2011 | -146.05 Thousand USD | -105.1% |
| 2010 | 2.86 Million USD | 235.86% |
| 2009 | -2.1 Million USD | 47.67% |
| 2008 | -4.02 Million USD | 21.6% |
| 2007 | -5.13 Million USD | -10.17% |
| 2006 | -4.66 Million USD | -49.24% |
| 2005 | -3.12 Million USD | 4.61% |
| 2004 | -3.27 Million USD | -310.23% |
| 2003 | -798.31 Thousand USD | 12.1% |
| 2002 | -908.24 Thousand USD | -3331.61% |
| 2001 | 28.1 Thousand USD | 101.34% |
| 2000 | -2.09 Million USD | -3275.96% |
| 1999 | 65.8 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -279 Thousand USD | -76.78% |
| 2024 Q1 | -157.82 Thousand USD | 76.55% |
| 2023 Q3 | -306.38 Thousand USD | -537.45% |
| 2023 Q1 | -934.34 Thousand USD | 45.56% |
| 2023 Q2 | -48.06 Thousand USD | 94.86% |
| 2023 FY | -673.08 Thousand USD | 60.78% |
| 2023 Q4 | -673.08 Thousand USD | -119.69% |
| 2022 Q2 | -3.09 Million USD | -424.65% |
| 2022 FY | -1.71 Million USD | -1056.21% |
| 2022 Q4 | -1.71 Million USD | 32.01% |
| 2022 Q3 | -2.52 Million USD | 18.37% |
| 2022 Q1 | -589.33 Thousand USD | -297.05% |
| 2021 Q1 | 161.43 Thousand USD | 206.5% |
| 2021 Q3 | -148.43 Thousand USD | 0.0% |
| 2021 Q4 | -148.43 Thousand USD | 0.0% |
| 2021 FY | -148.43 Thousand USD | 2.08% |
| 2020 Q4 | -151.58 Thousand USD | 0.0% |
| 2020 FY | -151.58 Thousand USD | -127.98% |
| 2019 Q4 | -157.26 Thousand USD | -140.05% |
| 2019 FY | 541.7 Thousand USD | 265.2% |
| 2019 Q1 | 145.65 Thousand USD | 144.42% |
| 2019 Q2 | 380.96 Thousand USD | 161.55% |
| 2019 Q3 | 392.67 Thousand USD | 3.07% |
| 2018 Q1 | -146.93 Thousand USD | 78.81% |
| 2018 Q4 | -327.91 Thousand USD | -40.43% |
| 2018 Q2 | -373.28 Thousand USD | -154.05% |
| 2018 Q3 | -233.5 Thousand USD | 37.45% |
| 2018 FY | -327.91 Thousand USD | 52.72% |
| 2017 Q3 | -1.92 Million USD | -480.96% |
| 2017 FY | -693.51 Thousand USD | 74.06% |
| 2017 Q1 | -1.33 Million USD | 49.96% |
| 2017 Q2 | -331.03 Thousand USD | 75.25% |
| 2017 Q4 | -693.51 Thousand USD | 63.94% |
| 2016 FY | -2.67 Million USD | -107.85% |
| 2016 Q2 | -6.06 Million USD | -116.48% |
| 2016 Q4 | -2.67 Million USD | 31.07% |
| 2016 Q3 | -3.87 Million USD | 36.07% |
| 2016 Q1 | 36.81 Million USD | 8.03% |
| 2015 Q2 | -6.34 Million USD | 44.37% |
| 2015 FY | 34.07 Million USD | 318.15% |
| 2015 Q1 | -11.39 Million USD | 27.04% |
| 2015 Q4 | 34.07 Million USD | 1117.74% |
| 2015 Q3 | -3.34 Million USD | 47.19% |
| 2014 Q2 | -24.77 Million USD | -352.32% |
| 2014 Q3 | -19.78 Million USD | 20.16% |
| 2014 Q4 | -15.62 Million USD | 21.04% |
| 2014 FY | -15.62 Million USD | -768.55% |
| 2014 Q1 | -5.47 Million USD | -334.46% |
| 2013 Q3 | 1.18 Million USD | -43.7% |
| 2013 Q2 | 2.11 Million USD | 280.45% |
| 2013 FY | 2.33 Million USD | 552.99% |
| 2013 Q4 | 2.33 Million USD | 96.42% |
| 2013 Q1 | -1.17 Million USD | -127.0% |
| 2012 FY | -515.8 Thousand USD | -253.17% |
| 2012 Q2 | -6.44 Million USD | -1.0% |
| 2012 Q4 | -515.8 Thousand USD | 86.18% |
| 2012 Q1 | -6.38 Million USD | -4269.05% |
| 2012 Q3 | -3.73 Million USD | 42.07% |
| 2011 Q2 | 1.79 Million USD | -26.65% |
| 2011 Q4 | -146.05 Thousand USD | -108.27% |
| 2011 FY | -146.05 Thousand USD | -105.1% |
| 2011 Q1 | 2.45 Million USD | -14.37% |
| 2011 Q3 | 1.76 Million USD | -1.81% |
| 2010 FY | 2.86 Million USD | 235.86% |
| 2010 Q1 | -1.22 Million USD | 41.73% |
| 2010 Q2 | 2.93 Million USD | 339.36% |
| 2010 Q3 | 3.38 Million USD | 15.27% |
| 2010 Q4 | 2.86 Million USD | -15.49% |
| 2009 Q4 | -2.1 Million USD | 23.47% |
| 2009 Q1 | -3.08 Million USD | 23.31% |
| 2009 FY | -2.1 Million USD | 47.67% |
| 2009 Q3 | -2.75 Million USD | -15.68% |
| 2009 Q2 | -2.38 Million USD | 22.91% |
| 2008 Q1 | -4.31 Million USD | 15.91% |
| 2008 Q4 | -4.02 Million USD | 15.08% |
| 2008 Q2 | -3.93 Million USD | 8.85% |
| 2008 FY | -4.02 Million USD | 21.6% |
| 2008 Q3 | -4.74 Million USD | -20.45% |
| 2007 Q2 | -3.73 Million USD | 12.32% |
| 2007 Q4 | -5.13 Million USD | -49.16% |
| 2007 FY | -5.13 Million USD | -10.17% |
| 2007 Q1 | -4.26 Million USD | 8.54% |
| 2007 Q3 | -3.44 Million USD | 7.89% |
| 2006 Q3 | -4.66 Million USD | 9.4% |
| 2006 FY | -4.66 Million USD | -49.24% |
| 2006 Q1 | -2.46 Million USD | 21.08% |
| 2006 Q2 | -5.14 Million USD | -108.85% |
| 2006 Q4 | -4.66 Million USD | 0.06% |
| 2005 FY | -3.12 Million USD | 4.61% |
| 2005 Q3 | -3.92 Million USD | 6.52% |
| 2005 Q2 | -4.19 Million USD | -0.78% |
| 2005 Q1 | -4.16 Million USD | -27.1% |
| 2005 Q4 | -3.12 Million USD | 20.34% |
| 2004 Q3 | -3.19 Million USD | 12.8% |
| 2004 Q4 | -3.27 Million USD | -2.45% |
| 2004 Q1 | -4.89 Million USD | -513.76% |
| 2004 FY | -3.27 Million USD | -310.23% |
| 2004 Q2 | -3.66 Million USD | 25.18% |
| 2003 Q2 | -965.06 Thousand USD | -97.73% |
| 2003 Q1 | -488.08 Thousand USD | 46.26% |
| 2003 FY | -798.31 Thousand USD | 12.1% |
| 2003 Q4 | -798.31 Thousand USD | 49.97% |
| 2003 Q3 | -1.59 Million USD | -65.33% |
| 2002 Q4 | -908.24 Thousand USD | 59.07% |
| 2002 Q2 | 696.14 Thousand USD | 273.0% |
| 2002 Q3 | -2.21 Million USD | -418.78% |
| 2002 FY | -908.24 Thousand USD | -3331.61% |
| 2002 Q1 | 186.63 Thousand USD | 564.06% |
| 2001 Q4 | 28.1 Thousand USD | 136.53% |
| 2001 Q2 | 3.68 Million USD | 35.59% |
| 2001 Q3 | -76.94 Thousand USD | -102.09% |
| 2001 Q1 | 2.71 Million USD | 229.97% |
| 2001 FY | 28.1 Thousand USD | 101.34% |
| 2000 FY | -2.09 Million USD | -3275.96% |
| 2000 Q4 | -2.09 Million USD | 47.75% |
| 2000 Q3 | -4 Million USD | 29.11% |
| 2000 Q2 | -5.64 Million USD | 21.6% |
| 2000 Q1 | -7.19 Million USD | 0.0% |
| 1999 FY | 65.8 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | -51280.84% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 111.917% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 101.573% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -169.645% |
| Rebus Holdings, Inc. | 305 Thousand USD | 320.685% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 89.324% |
| Qrons Inc. | 351.42 Thousand USD | 291.53% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 208.15% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 101.55% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -3198.162% |
| Skye Bioscience, Inc. | -5.72 Million USD | 88.236% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 104.27% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 116.345% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 267.498% |
| SQZ Biotechnologies Company | -36.23 Million USD | 98.143% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 130.019% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 172.595% |
| Mesoblast Limited | 55.85 Million USD | 101.205% |
| Marizyme, Inc. | 18.56 Million USD | 103.625% |
| Genus plc | 190.6 Million USD | 100.353% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 130.105% |
| Pharming Group N.V. | 109.8 Million USD | 100.613% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 178.244% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 155.449% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 198.984% |
| ContraFect Corporation | -6.02 Million USD | 88.83% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 599.921% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 158.254% |
| IMV Inc. | 7.67 Million USD | 108.775% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 112.234% |
| MultiCell Technologies, Inc. | 90.04 USD | 747644.425% |
| ONE Bio Corp. | 9.04 Million USD | 107.446% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 8.296% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 105.199% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 149.203% |
| Q BioMed Inc. | 4.06 Million USD | 116.579% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 102.203% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 166.794% |
| Biomind Labs Inc. | 711.4 Thousand USD | 194.614% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 101.112% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 133.665% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 105.256% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 287.12% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 581.452% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 3487.975% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 130.567% |
| GB Sciences, Inc. | 1.74 Million USD | 138.521% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -266.231% |
| HST Global, Inc. | 96.79 Thousand USD | 795.39% |
| CSL Limited | 10.52 Billion USD | 100.006% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 426.398% |
| Halberd Corporation | 144.72 Thousand USD | 565.094% |
| Enzolytics Inc. | 981.65 Thousand USD | 168.567% |
| Agentix Corp. | 37.63 Thousand USD | 1888.656% |
| Resverlogix Corp. | 6.45 Million USD | 110.434% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -2.02 Billion USD | 99.967% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 98.568% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 109.519% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 124.85% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 92.386% |
| AVAX Technologies, Inc. | -5.9 Million USD | 88.598% |
| Zenith Capital Corp. | 10.06 Thousand USD | 6788.086% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.937% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 435.819% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 128.21% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 509.15% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -3574.468% |
| Kadimastem Ltd | -253.1 Thousand USD | -165.936% |
| Helix BioMedix, Inc. | -2.57 Million USD | 73.81% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 103.32% |
| BioStem Technologies, Inc. | 4.47 Million USD | 115.051% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 434.448% |
| LadRx Corporation | -2.03 Million USD | 66.948% |
| Cell Source, Inc. | 9.23 Million USD | 107.291% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 205.97% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 205.97% |
| NovAccess Global Inc. | 2.17 Million USD | 130.897% |
| Affymax, Inc. | -5.59 Million USD | 87.974% |
| Itoco Inc. | 228.3 Thousand USD | 394.82% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 594.958% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 113.579% |
| Mobile Lads Corp. | 484.23 Thousand USD | 239.001% |
| CytoDyn Inc. | 20.26 Million USD | 103.322% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -103932.303% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -7162.239% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 108.735% |
| SYBLEU INC | 473.71 Thousand USD | 242.088% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 115.102% |
| International Stem Cell Corporation | 2.59 Million USD | 125.988% |
| Bioxytran, Inc. | 1.89 Million USD | 135.446% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 1178.444% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 130.863% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 119.601% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 107.87% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 187.119% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 46.153% |
| Neutra Corp. | 52.18 Thousand USD | 1389.764% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 72.957% |
| PureTech Health plc | -167.19 Million USD | 99.597% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -174.833% |
| IXICO plc | -4.44 Million USD | 84.856% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 105.092% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 101.227% |
| CSL Limited | 10.52 Billion USD | 100.006% |
| Cellectis S.A. | -43.81 Million USD | 98.464% |